Calliditas Therapeutics AB
11
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
Role: lead
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Role: lead
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Role: lead
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Role: lead
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
Role: lead
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
Role: lead
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
Role: lead
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Role: lead
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
Role: lead
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
Role: lead
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
Role: lead
All 11 trials loaded